
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp's stock exhibits a positive outlook supported by a recent 4% increase in share value, which reflects favorable market sentiment regarding the company's Phase 3 SAPPHIRE trial results. The stock is currently perceived as undervalued, trading at approximately 14 times net cash, indicating a favorable risk/reward profile over the next 12 to 24 months. Additionally, the successful resolution of regulatory observations at the contract development and manufacturing organization (CDMO) facility reinforces management's confidence in advancing their drug substance production and potential expedited regulatory approval.
Bears say
Scholar Rock Holding Corp is facing significant delays in the commercial launch of its lead product, apitegromab, now pushed back to 2026 in the US and 2026 in the EU, affecting peak sales estimates which have been reduced to $1.7 billion by 2035. The recent issuance of a Complete Response Letter (CRL) not only stalls the launch but also introduces increased regulatory hurdles and competitive risks associated with apitegromab, particularly in spinal muscular atrophy (SMA) and other indications. Additionally, the ongoing challenges with SRK-181 targeting TGFβ raise concerns about the drug's risk/benefit profile and the company's ability to navigate a competitive landscape, further contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares